
Nifty Falls Below 25,000, Sensex Slips Under 82,000 In Early Trade
Indian stock markets came under pressure on Friday as selling by Foreign Portfolio Investors (FPIs) weighed on investor sentiment.
At the time of reporting, the Nifty 50 stood at 25,010.35, down 51.75 points or 0.21 per cent, while the BSE Sensex was trading at 82,065.76, a decline of 118.41 points or 0.14 per cent.
Ajay Bagga, Banking and Market Expert, told ANI, "Indian markets are pointing to a continued negative outlook as per the traded futures. FPIs remain sellers while DIIs are absorbing the selling. Once more critical support levels are being challenged, so today's price action is important for the health of the Indian markets. Earnings continued to be weak on the whole, and with no US India Trade deal on the horizon before the August 1st deadline, markets are getting into a worry zone on that front."
He further added, "Fasten seat belts, we see key supports holding due to the blessed Indian retail investors who are determinedly buying every dip and keeping their faith in the Indian managements and economy even as FPIs are selling consistently."
Broad market indices on the NSE also reflected the pressure. The Nifty 100 was down by 0.53 per cent, Nifty Midcap 100 slipped by 0.34 per cent, and the Nifty Smallcap 100 lost 0.56 per cent. All other major indices were trading in the red.
Among the sectoral indices, Nifty Auto declined by 0.66 per cent, Nifty IT by 0.19 per cent, Nifty Media by 0.40 per cent, and Nifty Metal by 0.46 per cent. The only gainer at the time of filing the report was Nifty Pharma, which was up by 0.26 per cent.
Akshay Chinchalkar, Head of Research at Axis Securities, said, "The Nifty erased all its Wednesday gains yesterday, as it dropped 159 points to finish the day at 25062. Technically speaking, yesterday's candle completed yet another bearish engulfing, which means we have had two in quick succession - a rare event. The battle lines are clear: 25000 is vital support, while 25245 is key resistance. Bears will continue to have the upper hand until we have a daily close above 25340."
On the earnings front, several major companies are scheduled to release their quarterly results today, including Bajaj Finserv, Bank of Baroda, Cipla, Shriram Finance, SBI Cards & Payment Services, Schaeffler India, Steel Authority of India, Petronet LNG, Laurus Labs, Poonawalla Fincorp, Tata Chemicals, Aadhar Housing Finance, Grindwell Norton, and ACME Solar Holdings.
Meanwhile, global cues also remained weak. US-China trade talks scheduled in Sweden on Monday are expected to provide the next signal for the trajectory of US-India talks, especially as discussions on Russian oil supplies are also expected in Stockholm. With fiscal action lacking and the monetary policy meet slated for August 6, Indian markets are bracing for a potentially weak end to the week, marking what could be the fourth consecutive negative week.
In Asia, Japan's Nikkei 225 index was down 0.79 per cent, Singapore's Straits Times fell by 0.48 per cent, Hong Kong's Hang Seng declined by 1.19 per cent, and Taiwan's Weighted Index was marginally down by 0.08 per cent. South Korea's KOSPI was the only major gainer, up by 0.35 per cent.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
4 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —
&w=3840&q=100)

Business Standard
4 minutes ago
- Business Standard
Collaboration for future: Isro and India will benefit from Nasa
Artemis signup allows Isro and the fast-growing Indian aerospace sector to bid for Nasa tenders and the famously frugal Indian engineering sector could find opportunities there and pick up new skills Business Standard Editorial Comment Mumbai Listen to This Article The successful launch of the Nisar (Nasa-Isro Synthetic Aperture Radar) satellite from the Satish Dhawan Space Centre marks the second big mission where the two space agencies have joined hands, coming soon after gaganaut Shubhanshu Shukla travelled to the International Space Station on the Axiom 4 mission. This may be the precursor to more cooperation between the agencies, given that India in 2023 signed up for the Artemis Accords. The Artemis Accords provide a common set of principles for civil exploration and use of outer space. While both agencies benefit from cooperation, the Indian Space Research Organisation (Isro) may benefit


India Today
20 minutes ago
- India Today
How Trump tariffs could impact Indian pharma's $8.7 bn dream run
For long, the high-value US market has driven the growth of the storied Indian generic drugs industry, where companies like Cipla, Sun Pharma and Dr Reddy's Laboratories, among others, have successfully challenged hundreds of off-patent drugs in the US and established a soaring business FY24, India exported $8.7 billion (Rs 76,113 crore) worth of pharma products to the US, which comprises over 11 per cent of India's total merchandise exports to that the same period, India exported $77.5 billion (Rs 6.8 lakh crore) worth of merchandise goods to the US and imported $42.2 billion (Rs 3.7 lakh crore) worth of goods from it, resulting in a trade surplus of $35.3 billion (Rs 3 lakh crore) in India's US is India's largest destination for pharma exports, accounting for over 31 per cent of the country's total pharmaceutical exports. As much as 47 per cent of all generics consumed in the US are imported from India. However, the Donald Trump administration's threat of imposition of a 25 per cent reciprocal tariff from August 1 (up from 0 to 6.7 per cent at present) has thrown the Indian pharma industry in a bind. Shares of Indian pharma companies, led by Sun Pharma, fell close to 6 per cent on the NSE (National Stock Exchange) on August 1 following president Trump's statements on the tariff imposition, and his letters to 17 top US pharma companies asking them to reduce their rates in line with what prevailed in other countries. Some fear Trump may send a similar letter to Sun Pharma, which earns as much as 20 per cent of its total revenues from the US Indian industry was hoping against hope that Trump would not hike tariffs on generic drugs since these are life-saving. However, Trump had indicated earlier this year too that tariffs on pharma products would be 25 per cent from April 2 onwards, without pinpointing any nation. He later gave a 90-day reprieve to countries, and the new deadline for the tariffs was put as August imports roughly $800 million worth of pharmaceutical products from the US, and imposes a tariff of 10 per cent. Experts say that even if higher tariffs are imposed on active pharma ingredients (APIs), which are raw materials going into pharma production, India could still be competitive, if tariffs on other API-supplying countries are higher than that of the US will still be dependent on countries like India since the cost of manufacturing certain drugs in the US would be at least six times compared to that of manufacturing the same product in India, say industry US market, which relies heavily on India for APIs and low-cost generics, would struggle to find alternatives, according to Namit Joshi, chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India). 'Efforts to shift pharmaceutical manufacturing and API production to other countries or within the US will take at least 3-5 years to establish meaningful capacity,' he was quoted in media reports. advertisement'There is no need for panic. The industry should lie low for now since the US has not yet increased the tariffs. Who else can give the US such competitively-priced goods in large quantities and high quality?' Daara Patel, secretary general of the Indian Drug Manufacturers Association, had said in an interview to INDIA TODAY in April. 'Even if it increases up to 10 per cent, the industry should be able to absorb it or pass it on to the US consumers. They would not mind paying for it since it all works on insurance money,' he what if the US decides to go for a higher tariff? 'In case the US raises tariffs beyond 15 per cent, India will have to look at newer markets in East Africa and the Middle East. These markets are neither high value nor high in volumes, but it will be a better option than dealing with an uncertain US market alone,' Patel had saidSubscribe to India Today Magazine- EndsTune InMust Watch